Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Schering-Plough Reports on Hep C Drug

By Drug Discovery Trends Editor | November 2, 2009

NEW YORK (AP) – Schering-Plough Corp. said its experimental hepatitis C drug boceprevir helped eliminate the virus in about half of patients who did not respond to standard treatments.

Boceprevir is considered one of the most important products being developed by the Kenilworth, N.J., drugmaker, which is being acquired by Merck & Co. for $41.1 billion.

Initial results from the late-stage study, called Sprint-1, were reported earlier this year, but Schering-Plough reported the results of patients who had no response to other drugs, a hard-to-treat group called “null responders.”

A total of 50 patients were found to be “null responders” after four weeks of standard treatment.

After 28 weeks of treatment, Schering-Plough said 25 percent of the null responders had a “sustained virologic response,” meaning their virus levels were too low to measure. After 48 weeks of treatment, 55 percent of patients had a sustained virologic response.

“When you add boceprevir to these individuals, these null responders, you can get a sustained response, a cure of up to 55 percent, in the most difficult-to-treat individuals,” said Paul Kwo, the principal investigator in the study.

The result was similar to data reported by Vertex Pharmaceuticals Inc. on Wednesday. Vertex said 57 percent of null responders had a sustained response after 48 weeks of treatment with the company’s drug telaprevir.

The results were presented in Boston at a meeting of the American Associated for the Study of Liver Diseases.

The most common side effects in the Schering study were fatigue, anemia, nausea and headache. About half of the boceprevir patients developed anemia, a frequent side effect of hepatitis C drugs, compared to a third of the patients who did not receive the drug. Patients who took boceprevir were more likely to stop treatment than those who did not, but they had fewer relapses.

Schering-Plough is running a larger late-stage clinical trial of boceprevir on null responders, and a separate study on patients with untreated hepatitis C.

Date: November 2, 2009
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE